Aspen's strong business foundation in SA has provided the launching pad for global expansion, with strategic investments in the UK and Australia. But the SA environment is vulnerable to regulatory volatility, with uncertainty over possible price-capping. On the other hand, the company has proved adept at negotiating with government and is well-placed for further provision of generic drugs used to treat HIV/Aids. Since its JSE listing in the reverse takeover of Medhold in 1998, the group has grown strongly.
BDFM Publishers (Pty) Ltd disclaims all liability for any loss, damage, injury or expense however caused, arising from the use of, or reliance upon, in any manner, the information provided through this service and does not warrant the truth, accuracy or completeness of the information provided. The publisher's permission is required to reproduce the contents in any form including, capture into a database, website, intranet or extranet.
